Literature DB >> 33494968

Economic burden of influenza illness among children under 5 years in Suzhou, China: Report from the cost surveys during 2011/12 to 2016/17 influenza seasons.

Yin Wang1, Liling Chen2, Fangfang Cheng3, Matthew Biggerstaff4, Sujian Situ5, Suizan Zhou4, Junmei Gao6, Changpeng Liu6, Jun Zhang2, Alexander J Millman4, Tao Zhang6, Jianmei Tian7, Genming Zhao8.   

Abstract

BACKGROUND: Data are limited on the economic burden of seasonal influenza in China. We estimated the cost due to influenza illness among children < 5-year-old in Suzhou, China.
METHODS: This study adopted a societal perspective to estimate direct medical cost, direct non-medical cost, and indirect cost related to lost productivity. Data to calculate costs and rates of three influenza illness outcomes (non-medically attended, outpatient and hospitalization) were collected from prospective community-based cohort studies and hospital-based enhanced laboratory-confirmed influenza surveillance in Suzhou during the 2011/12 to 2016/17 influenza seasons. We used mean cost-per-episode, annual incidence rates of episodes of each outcome, and annual population size to estimate the total annual economic burden of influenza illnesses among children < 5-year-old for Suzhou. All costs were reported in 2017 U.S. dollars.
RESULTS: The mean cost-per-episode (standard deviation) was $9.92 (13.26) for non-medically attended influenza, $161.05 (176.98) for influenza outpatient illnesses, and $1425.95 (603.59) for influenza hospitalizations. By applying the annual incidence rates to the population size, we estimated an annual total of 4,919 episodes of non-medically attended influenza, 21,994 influenza outpatient, and 2,633 influenza hospitalization. Total annual economic burden of influenza to society among children < 5-year-old in Suzhou was $7.37 (95% confidence interval, 6.9-7.8) million, with estimated costs for non-medically attended influenza of $49,000 (46,000-52,000), influenza outpatients $3.5 (3.3-3.8) million, and influenza hospitalizations $3.8 (3.6-3.9) million. Among outpatients, the indirect cost was 36.3% ($1.3 million) of total economic burden, accounting for 21,994 days of lost productivity annually. Among inpatients, the indirect cost was 22.1% ($829,000), accounting for 18,431 days of lost productivity annually.
CONCLUSIONS: Our findings show that influenza in children < 5-year-oldcauses substantial societal economic burden in Suzhou, China. Assessing the potential economic benefit of increasing influenza vaccination coverage in this population is warranted.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Children; China; Direct cost; Economic burden; Indirect cost; Influenza

Mesh:

Year:  2021        PMID: 33494968      PMCID: PMC9008708          DOI: 10.1016/j.vaccine.2020.12.075

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  30 in total

1.  Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study.

Authors:  Kathleen M Neuzil; Yuwei Zhu; Marie R Griffin; Kathryn M Edwards; Juliette M Thompson; Sharon J Tollefson; Peter F Wright
Journal:  J Infect Dis       Date:  2001-12-17       Impact factor: 5.226

2.  The annual impact of seasonal influenza in the US: measuring disease burden and costs.

Authors:  Noelle-Angelique M Molinari; Ismael R Ortega-Sanchez; Mark L Messonnier; William W Thompson; Pascale M Wortley; Eric Weintraub; Carolyn B Bridges
Journal:  Vaccine       Date:  2007-04-20       Impact factor: 3.641

3.  Potential impact of B lineage mismatch on trivalent influenza vaccine effectiveness during the 2015-2016 influenza season among nursery school children in Suzhou, China.

Authors:  Yin Wang; Liling Chen; Yuejia Cheng; Suizan Zhou; Yuanyuan Pang; Jun Zhang; Carolyn M Greene; Ying Song; Tao Zhang; Genming Zhao
Journal:  Hum Vaccin Immunother       Date:  2017-12-06       Impact factor: 3.452

4.  Estimated influenza illnesses and hospitalizations averted by influenza vaccination among children aged 6-59 months in Suzhou, China, 2011/12 to 2015/16 influenza seasons.

Authors:  Wanqing Zhang; Junmei Gao; Liling Chen; Jianmei Tian; Matthew Biggerstaff; Suizan Zhou; Sujian Situ; Yin Wang; Jun Zhang; Alexander J Millman; Carolyn M Greene; Tao Zhang; Genming Zhao
Journal:  Vaccine       Date:  2020-11-08       Impact factor: 3.641

5.  Influenza-associated hospitalizations in the United States.

Authors:  William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Carolyn B Bridges; Nancy J Cox; Keiji Fukuda
Journal:  JAMA       Date:  2004-09-15       Impact factor: 56.272

6.  The cost of influenza-associated hospitalizations and outpatient visits in Kenya.

Authors:  Gideon O Emukule; Linus K Ndegwa; Michael L Washington; John W Paget; Jazmin Duque; Sandra S Chaves; Nancy A Otieno; Kabura Wamburu; Irene W Ndigirigi; Philip M Muthoka; Koos van der Velden; Joshua A Mott
Journal:  BMC Public Health       Date:  2019-05-10       Impact factor: 3.295

Review 7.  Is influenza-like illness a useful concept and an appropriate test of influenza vaccine effectiveness?

Authors:  Roger E Thomas
Journal:  Vaccine       Date:  2014-02-28       Impact factor: 3.641

8.  Epidemiologic and economic burden of influenza in the outpatient setting: a prospective study in a subtropical area of China.

Authors:  Ru-ning Guo; Hui-zhen Zheng; Li-qun Huang; Yong Zhou; Xin Zhang; Chan-kun Liang; Jin-yan Lin; Jian-feng He; Jin-qing Zhang
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

9.  Seasonal influenza vaccination coverage rate of target groups in selected cities and provinces in China by season (2009/10 to 2011/12).

Authors:  Lei Zhou; Qiru Su; Zhen Xu; Ao Feng; Hui Jin; Shiyuan Wang; Zijian Feng
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

10.  Low coverage of influenza vaccination among Chinese children aged 12-23 months: Prevalence and associated factors.

Authors:  Joseph T F Lau; Catalina S M Ng; Anise M S Wu; Yee Ling Ma; Mason M C Lau
Journal:  PLoS One       Date:  2018-10-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.